Barclays lowered the firm’s price target on Surgery Partners (SGRY) to $31 from $32 and keeps an Equal Weight rating on the shares post the Q3 report. The firm says the company’s operating backdrop remains favorable, but “idiosyncratic challenges slightly extend the free cash flow ramp.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners price target lowered to $34 from $35 at Macquarie
- Surgery Partners Reports Q3 Revenue Growth Amid Challenges
- Surgery Partners reports Q3 adjusted EPS 19c, consensus 25c
- Surgery Partners sees FY24 revenue greater than $3.075B, consensus $3.09B
- SGRY Earnings Report this Week: Is It a Buy, Ahead of Earnings?